title: NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.
abstract: Prostate cancer represents a spectrum of disease that ranges from nonaggressive, slow-growing disease that may not require treatment to aggressive, fast-growing disease that does. The NCCN Guidelines for Prostate Cancer Early Detection provide a set of sequential recommendations detailing a screening and evaluation strategy for maximizing the detection of prostate cancer that is potentially curable and that, if left undetected, represents a risk to the patient. The guidelines were developed for healthy men who have elected to participate in the early detection of prostate cancer, and they focus on minimizing unnecessary procedures and limiting the detection of indolent disease.
authors.forename: Peter R
authors.initials: PR
authors.lastname: Carroll
authors.forename: J Kellogg
authors.initials: JK
authors.lastname: Parsons
authors.forename: Gerald
authors.initials: G
authors.lastname: Andriole
authors.forename: Robert R
authors.initials: RR
authors.lastname: Bahnson
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Barocas
authors.forename: Erik P
authors.initials: EP
authors.lastname: Castle
authors.forename: William J
authors.initials: WJ
authors.lastname: Catalona
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Dahl
authors.forename: John W
authors.initials: JW
authors.lastname: Davis
authors.forename: Jonathan I
authors.initials: JI
authors.lastname: Epstein
authors.forename: Ruth B
authors.initials: RB
authors.lastname: Etzioni
authors.forename: Thomas
authors.initials: T
authors.lastname: Farrington
authors.forename: George P
authors.initials: GP
authors.lastname: Hemstreet
authors.forename: Mark H
authors.initials: MH
authors.lastname: Kawachi
authors.forename: Paul H
authors.initials: PH
authors.lastname: Lange
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Loughlin
authors.forename: William
authors.initials: W
authors.lastname: Lowrance
authors.forename: Paul
authors.initials: P
authors.lastname: Maroni
authors.forename: James
authors.initials: J
authors.lastname: Mohler
authors.forename: Todd M
authors.initials: TM
authors.lastname: Morgan
authors.forename: Robert B
authors.initials: RB
authors.lastname: Nadler
authors.forename: Michael
authors.initials: M
authors.lastname: Poch
authors.forename: Chuck
authors.initials: C
authors.lastname: Scales
authors.forename: Terrence M
authors.initials: TM
authors.lastname: Shaneyfelt
authors.forename: Marc C
authors.initials: MC
authors.lastname: Smaldone
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Sonn
authors.forename: Preston
authors.initials: P
authors.lastname: Sprenke
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Vickers
authors.forename: Robert
authors.initials: R
authors.lastname: Wake
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Shead
authors.forename: Deborah
authors.initials: D
authors.lastname: Freedman-Cass
mesh_terms: D015415:Biomarkers; D001706:Biopsy / Q000379:methods; D003952:Diagnostic Imaging / Q000379:methods; D055088:Early Detection of Cancer / Q000379:methods; D006801:Humans; D008297:Male; D008403:Mass Screening; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology
chemical_list: D015415:Biomarkers